Dr Patricia Roxburgh

  • Clinical Senior Lecturer (Experimental Therapeutics)

Research interests

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • the PEACE study
    NHS Greater Glasgow and Clyde
    2018 - 2021
     
  • Precision Medicine Laboratory sequencing of patient tumour samples
    Beatson Cancer Charity
    2017 - 2022
     
  • Developing personalised therapy for women with ovarian cancer
    Beatson Cancer Charity
    2016 - 2019
     
  • The relationship between p53 mutation and inflammation in high-grade serous ovarian cancer
    Academy of Medical Sciences
    2014 - 2015
     
  • p53 mutation as a biomarker for response to anti-EGFR therapy in metastatic colorectal cancer
    Cancer Research UK
    2010 - 2012
     

Publications

List by: Type | Date

Jump to: 2017 | 2014 | 2013 | 2011 | 2010 | 2008
Number of items: 13.

2017

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi:10.1038/bjc.2017.36) (PMID:28222073)

2014

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi:10.1097/IGC.0000000000000060)

Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi:10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)

Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi:10.1007/s11912-014-0413-1)

2013

Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi:10.1016/j.bmc.2013.09.038)

Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi:10.2217/fon.13.60)

Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi:10.1016/j.ejca.2012.11.016)

Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi:10.1093/carcin/bgs092)

2011

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi:10.1158/1078-0432.CCR-10-2159)

Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),

2010

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi:10.1200/JCO.2009.25.1082)

2008

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi:10.1007/s12325-008-0113-z)

This list was generated on Tue Jun 18 16:24:05 2019 BST.
Jump to: Articles
Number of items: 13.

Articles

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi:10.1038/bjc.2017.36) (PMID:28222073)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi:10.1097/IGC.0000000000000060)

Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi:10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)

Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi:10.1007/s11912-014-0413-1)

Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi:10.1016/j.bmc.2013.09.038)

Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi:10.2217/fon.13.60)

Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi:10.1016/j.ejca.2012.11.016)

Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi:10.1093/carcin/bgs092)

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi:10.1158/1078-0432.CCR-10-2159)

Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi:10.1200/JCO.2009.25.1082)

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi:10.1007/s12325-008-0113-z)

This list was generated on Tue Jun 18 16:24:05 2019 BST.